MedTrace Logo

Enhancing Rehabilitation in Aging Study (ERAS)

NCT07704385 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2026-07-15

No results posted yet for this study

Summary

Acute Intermittent Hypoxia (AIH) is a rehab approach attributed to serotonin. AIH signaling also occurs via adenosine, and the pathways inhibit each other. Increased neural adenosine in aging may stymie AIH plasticity. The hypothesis is pre-treatment with adenosine 2A receptor inhibition (A2AI) enhances AIH effects on motor plasticity in unaffected adults. AIH exposures will be paired with A2AI or placebo, with a 4-week washout. Primary outcome measures include inspiratory and grip strength.

Conditions

  • Adults

Interventions

DRUG

Istradefylline 20 mg

Participants will receive 20 mg istradefylline active treatment, followed by acute intermittent hypoxia

DRUG

Placebo

Participants will receive a methylcellulose capsule identical in appearance to the active treatment, followed by acute intermittent hypoxia

OTHER

Acute Intermittent Hypoxia (AIH)

Short periods (\~1 minute) of breathing lower-oxygen gas, separated by periods (\~1 minute) of breathing normal oxygen air.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2031-05-31
Completion
2031-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07704385 on ClinicalTrials.gov